先进治疗药物市场规模、份额、趋势分析报告：按治疗产品类型、地区和细分市场预测，2023-2030 年

先进治疗药物市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球先进治疗药物市场规模预计将达到909.8亿美元，预测期内复合年增长率为16.8%。

ATMP（先进治疗药品）代表着透过解决根本原因而不是症状治疗来治癒疾病的可能性。因此，ATMP 有助于提供传统治疗方法无法提供的创新益处。预计这些因素将在预测期内推动市场。

继 Zolgensma、Kymriah 和 Yescarta核准之后，Tecartus 和 Abecma 的突破性核准正在推动该领域取得显着进展。这些核准正在刺激该行业的投资流入并推动收益成长。主要企业正在采用各种营运模式来加速其产品製造流程。

此外，我们也看到有意进入该行业或扩大现有业务的公司进行了几起收购。最近的例子包括吉利德生命科学公司收购 Kite Pharma、诺华公司收购 AveXis 以及新基公司收购 Juno Therapeutics。这些收购显示老牌製药公司对该市场的兴趣日益浓厚。基因疗法的收购竞争非常激烈，溢价也很高。

同时，随着消费者需求的增加，ATMP 製造商越来越多地将产品製造外包，为受託製造厂商创造了利润丰厚的机会。因此，一些 CDMO 正在扩大其设施。例如，2021年1月，FUJIFILM Diosynth Biotechnologies投资4000万美元开发新製程并建立先进疗法和病毒载体的製造工厂。

先进治疗药物市场报告亮点

• Yescarta 和 Kymriah 在日本和欧洲的地域扩张正在鼓励投资者支持该领域的发展。
• 最近基因疗法的核准大大加速了该领域的临床试验。
• COVID-19 大流行为主要企业投资抗病毒感染疾病的T 细胞研究开拓了新领域。
• 研究界正在积极评估针对 COVID-19 患者的先进治疗的潜力，以帮助市场成长。
• 由于先进治疗的临床试验急剧增加，北美在 2022 年占据了最大的销售份额。
• 在美国，ATMP 强大的产品线加速了该地区的产生收入。
• 美国公司将重点从传统药物开发转向 ATMPS，也支持了该地区的成长。
• 由于以中国为首的新兴市场中 ATMP 市场的扩张，亚太地区预计将出现最快的市场复合年增长率。
• 中国 CDMO 的扩张正在推动区域市场的成长。
• 主要企业正在采取各种策略措施来维持其市场地位。 ViGeneron GmbH 与 Biogen Inc. 于 2021 年 1 月建立的合作关係是该领域合作的着名例子之一。
• 两家公司合作开发以 AAV 为基础的基因治疗产品，用于治疗遗传性眼科疾病。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章先进治疗药物市场变数、趋势与范围

• 市场体系展望
  • 母市场展望
  • 相关/附随市场展望
• 普及和成长前景图
• 市场动态
  • 市场驱动因素分析
  • 市场抑制因素分析
• 先进治疗市场分析工具
  • 产业分析-波特五力分析
  • PESTEL分析

第四章 先进治疗药物：种类估算及趋势分析

• 先进治疗药物市场：要点
• 先进治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
• 细胞疗法
• 基因治疗
• 组织工程产品

第五章先进治疗药物市场：区域估计与趋势分析

• 区域展望
• 按地区分類的先进治疗市场：主要市场亮点
• 北美洲
  • 2018-2030 年市场估计与预测
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 瑞典
  • 挪威
  • 丹麦
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 泰国
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东/非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿拉伯聯合大公国
  • 科威特

第六章竞争形势

• 主要市场参与企业的最新趋势和影响分析
• 公司/竞争分类
  • Spark Therapeutics, Inc.
  • Bluebird Bio, Inc
  • Novartis AG
  • UniQure NV
  • Celgene Corporation
  • Gilead Lifesciences, Inc
  • Kolon TissueGene, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • MEDIPOST
  • Vericel Corporation
  • PHARMICELL Co., Ltd
  • Organogenesis Inc.

Advanced Therapy Medicinal Products Market Growth & Trends:

The global advanced therapy medicinal products market size is expected to reach USD 90.98 billion by 2030, registering a CAGR of 16.8% during the forecast period, according to a new report by Grand View Research, Inc. The ATMPs (Advanced Therapy Medicinal Products) exhibit the potential to cure diseases by addressing their root cause rather than symptomatic treatment. Thus, ATMPs help deliver transformative advantages which are not offered by conventional treatments. These factors are expected to drive the market over the forecast period.

The breakthrough approvals of Tecartus and Abecma post-approval of Zolgensma, Kymriah, and Yescarta have bolstered the exceptional advancements in this space. These approvals have spurred the investment flow in this arena thereby driving revenue growth. Key companies are adopting various operation models to accelerate the product manufacturing process.

Furthermore, the market witnessed several acquisitions by players that intended to enter or expand their existing business in this field. Acquisitions of Kite Pharma by Gilead Life Science, AveXis by Novartis, and Juno Therapeutics by Celgene are some major & recent examples. These acquisitions depict the increasing interest of well-established pharma companies in this market. Increasing competition for gene therapy buyouts can lead to hefty premiums.

On the other hand, with the growing consumer demands, the ATMP manufacturers are outsourcing their product manufacturing thereby creating lucrative opportunities for the contract manufacturing organizations. Thus, several CDMOs have expanded their facilities. For instance, in January 2021, FUJIFILM Diosynth Biotechnologies invested USD 40 million for the establishment of a new process development and manufacturing facility for advanced therapies and viral vectors.

Advanced Therapy Medicinal Products Market Report Highlights:

• The geographical expansion of Yescarta and Kymriah in Japan and Europe has encouraged the investors to support the development in this space
• Recent approvals of gene therapies have significantly accelerated the clinical trials in this segment
• COVID-19 pandemic has opened new areas for key players to invest in T-cell research for viral infections
• The research community is actively evaluating the potential of advanced therapies in COVID-19 patients, thereby aiding in market growth
• North America accounted for the largest revenue share in 2022 owing to the exponential rise in clinical trials pertaining to advanced therapies
• Strong pipeline of ATMPs in the U.S. accelerated revenue generation in the region
• Also, the shifting focus of U.S.-based companies from conventional drug development to ATMPS is driving regional growth
• In Asia Pacific, the market is expected to witness the fastest CAGR owing to expanding ATMP landscape in emerging markets such as China at the forefront
• Expanding business of China-based CDMOs has driven regional market growth
• Key companies are undertaking various strategic initiatives to maintain their market position. Collaboration between ViGeneron GmbH and Biogen Inc. in January 2021 is one of the notable examples of collaboration in this space
• The companies collaborated on the development of an AAV-based gene therapy product for the treatment of inherited eye diseases.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Therapy Type
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Therapy type outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Advanced Therapy Medicinal Products Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Advanced Therapy Medicinal Products Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Advanced Therapy Medicinal Products: Type Estimates & Trend Analysis

• 4.1. Advanced Therapy Medicinal Products Market: Key Takeaways
• 4.2. Advanced Therapy Medicinal Products Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Cell Therapy
  • 4.3.1. Cell therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Gene Therapy
  • 4.4.1. Gene therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Tissue Engineered Product
  • 4.5.1. Tissue engineered product market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Advanced Therapy Medicinal Product Market: Regional Estimates & Trend Analysis

• 5.1. Regional Outlook
• 5.2. Advanced Therapy Medicinal Products Market by Region: Key Marketplace Takeaway
• 5.3. North America
  • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.3.2. U.S.
    • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.3.3. Canada
    • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.4. Europe
  • 5.4.1. UK
    • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.2. Germany
    • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.3. France
    • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.4. Italy
    • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.5. Spain
    • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.6. Sweden
    • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.7. Norway
    • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.8. Denmark
    • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Japan
    • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5.2. China
    • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5.3. India
    • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5.4. Australia
    • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5.5. Thailand
    • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5.6. South Korea
    • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.6. Latin America
  • 5.6.1. Brazil
    • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6.2. Mexico
    • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6.3. Argentina
    • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.7. MEA
  • 5.7.1. Saudi Arabia
    • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7.2. South Africa
    • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7.3. UAE
    • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7.4. Kuwait
    • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
  • 6.2.1. Spark Therapeutics, Inc.
    • 6.2.1.1. Company overview
    • 6.2.1.2. Financial performance
    • 6.2.1.3. Product benchmarking
    • 6.2.1.4. Strategic initiatives
  • 6.2.2. Bluebird Bio, Inc
    • 6.2.2.1. Company overview
    • 6.2.2.2. Financial performance
    • 6.2.2.3. Product benchmarking
    • 6.2.2.4. Strategic initiatives
  • 6.2.3. Novartis AG
    • 6.2.3.1. Company overview
    • 6.2.3.2. Financial performance
    • 6.2.3.3. Product benchmarking
    • 6.2.3.4. Strategic initiatives
  • 6.2.4. UniQure N.V.
    • 6.2.4.1. Company overview
    • 6.2.4.2. Financial performance
    • 6.2.4.3. Product benchmarking
    • 6.2.4.4. Strategic initiatives
  • 6.2.5. Celgene Corporation
    • 6.2.5.1. Company overview
    • 6.2.5.2. Financial performance
    • 6.2.5.3. Product benchmarking
    • 6.2.5.4. Strategic initiatives
  • 6.2.6. Gilead Lifesciences, Inc
    • 6.2.6.1. Company overview
    • 6.2.6.2. Financial performance
    • 6.2.6.3. Product benchmarking
    • 6.2.6.4. Strategic initiatives
  • 6.2.7. Kolon TissueGene, Inc
    • 6.2.7.1. Company overview
    • 6.2.7.2. Financial performance
    • 6.2.7.3. Product benchmarking
    • 6.2.7.4. Strategic initiatives
  • 6.2.8. JCR Pharmaceuticals Co., Ltd.
    • 6.2.8.1. Company overview
    • 6.2.8.2. Financial performance
    • 6.2.8.3. Product benchmarking
    • 6.2.8.4. Strategic initiatives
  • 6.2.9. MEDIPOST
    • 6.2.9.1. Company overview
    • 6.2.9.2. Financial performance
    • 6.2.9.3. Product benchmarking
    • 6.2.9.4. Strategic initiatives
  • 6.2.10. Vericel Corporation
    • 6.2.10.1. Company overview
    • 6.2.10.2. Financial performance
    • 6.2.10.3. Product benchmarking
    • 6.2.10.4. Strategic initiatives
  • 6.2.11. PHARMICELL Co., Ltd
    • 6.2.11.1. Company overview
    • 6.2.11.2. Financial performance
    • 6.2.11.3. Product benchmarking
    • 6.2.11.4. Strategic initiatives
  • 6.2.12. Organogenesis Inc.
    • 6.2.12.1. Company overview
    • 6.2.12.2. Financial performance
    • 6.2.12.3. Product benchmarking
    • 6.2.12.4. Strategic initiatives

List of Tables

• Table 1 List of Abbreviation
• Table 2 North America advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 3 North America advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
• Table 4 U.S. advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 5 Canada advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 6 Europe advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 7 Europe advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
• Table 8 Germany advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 9 UK advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 10 France advanced therapy medicinal products, by therapy type, 2018 - 2030 (USD Million)
• Table 11 Italy advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 12 Spain advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 13 Sweden advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 14 Norway advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 15 Denmark advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 16 Asia Pacific advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 17 Asia Pacific advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
• Table 18 China advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 19 Japan advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 20 India advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 21 Thailand advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 22 South Korea advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 23 Latin America advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 24 Latin America advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
• Table 25 Brazil advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 26 Mexico advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 27 Argentina advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 28 Middle East and Africa advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 29 Middle East and Africa advanced therapy medicinal products market, by region, 2018 - 2030 (USD Million)
• Table 30 South Africa advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 31 Saudi Arabia advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 32 UAE advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)
• Table 33 Kuwait advanced therapy medicinal products market, by therapy type, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Advanced therapy medicinal products: market outlook
• Fig. 9 Parent market outlook
• Fig. 10 Related/ancillary market outlook
• Fig. 11 Penetration and growth prospect mapping
• Fig. 12 Industry value chain analysis
• Fig. 13 Advanced therapy medicinal products market driver impact
• Fig. 14 Advanced therapy medicinal products market restraint impact
• Fig. 15 Advanced therapy medicinal products market strategic initiatives analysis
• Fig. 16 Advanced therapy medicinal products market: type movement analysis
• Fig. 17 Advanced therapy medicinal products market: type outlook and key takeaways
• Fig. 18 Cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 Gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Tissue engineered product market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Global Advanced therapy medicinal products market: regional movement analysis
• Fig. 22 Global Advanced therapy medicinal products market: regional outlook and key takeaways
• Fig. 23 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)